'Red yeast rice' as a cholesterol-lowering substance?Caution is warranted;'Rode gist rijst' als cholesterolverlager?: EEN WAARSCHUWING IS OP ZIJN PLAATS

Nederlands Tijdschrift voor Geneeskunde

Volumn 160, Issue 32, 2016, Pages

  Brouwers Koos, J R B J ^a,b   Van Lennep Roeters, Jeanine E R ^c   Maas, Angela H E M ^d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b EPHOR Expertisecentrum Pharmacotherapie Bij Ouderen   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; BIOLOGICAL PRODUCT;

ARTICLE; DRUG CONTROL; DRUG INTERACTION; DRUG QUALITY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH HAZARD; HUMAN; NETHERLANDS; PHARMACIST; PREGNANCY; REGISTRATION; RISK REDUCTION; DIETARY SUPPLEMENT; HYPERCHOLESTEROLEMIA; PHYTOTHERAPY;

BIOLOGICAL PRODUCTS; DIETARY SUPPLEMENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOVASTATIN; NETHERLANDS; PHYTOTHERAPY;

EID: 84991073436     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on assessment, aethiology and management. Eur Heart J. 2015;36:1012-22.
2. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Scientific opinion on the substantiation of health claims related to monacoline K from red yeast rice and maintenance of normal blood levels LDL cholesterol concentrations. EFSA Journal. 2011;9:2304.
3. Childress L, Gay A, Zargar A, Ito MK. Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol. 2013;7:117-22.
4. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products. Arch. Intern Med. 2010;170:1722-7.
5. Gerards MC, Terlou RJ, Yu H, Koks CHW, Gerdes VEA. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis. 2015;240:415-23.
6. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta analysis of randomized controlled trials. Chin Med. 2006;1:4.
7. Yang CW, Mousa SA. The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Compl Ther Med. 2012;20:466-74.
8. Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS ONE. 2014;9:e98611.
9. Burke FM. Red yeast rice for the treatment of dyslipidemia. Curr Atheroscler Rep. 2015;17:495.
10. Xiong X, Wang P, Li X, Zhang Y, Li S. The effect of red yeast rice dietary supplement on blood pressure, lipid profile and CRP in hypertension: a systematic review Crit Rev Food Sci Nutr. 13 juli 2015 (epub).
11. Ong YC, Aziz Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. J Clin Pharm Therap. 2016;41:170-9.
12. Downs JR, Clearfield M, Weis S, et al; for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
13. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830-9.
14. Gonnelli S, Caffarelli C, Stolakis K, Cuda C, Giordano N, Nuti R. Efficacy and tolerability of a nutraceutical (red yeast rice, polycosanols, and berberine) in patients with low-moderate risk hypercholesterolemia: a double blind, placebo-controlled trial. Curr Ther Res Clin Exp. 2014;77:1-6.
15. Lu Z, Kou W, Du B, et al; Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689-93.
16. Ye P, Lu Z-L, Du BM, et al; CCSPS Investigators. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. J Am Geriatr Soc. 2007;55:1015-22.
17. Philibert C, Bres V, Jean-Pastor MJ, Guy C, Lebrun-Vignes B, Robin P, et al. [Read yeast rice induced muscular injuries: analysis of French pharmacovigilance database and literature review] (Frans). Thérapie. oktober 2015 (epub).
18. Menniti-Ippolito F, Da Cas R, Moro PA, Mazzanti G. Safety of red rice yeast food supplements [abstract nr. O42; 15th ISoP Annual Meeting "Cubism in Pharmacovigiliance, Praag, 2015]. Drug Saf. 2015;38:954.
19. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105:198-204.
20. Ganga HV, Slim HB, Thompson PD. A systematic review of statininduced muscle problems in clinical trials. Am Heart J. 2014;168:6-15.
21. Rosano GMC, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J. 2015;36:2677-80.
22. Hsue PY, Bittner VA, Betteridge J, et al. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Am J Cardiol. 2015;115:447-53.
23. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
24. Upchurch DM, Chyu L. Use of complementary and alternative medicine among American women. Womens Health Issues. 2005;15:5-13.
25. Gemeente Amsterdam. Onderzoek, Informatie en Statistiek. www.ois. amsterdam.nl, geraadpleegd op 29 maart 2016.
26. Pickering TG. The Food and Drug Administration and over-the-counter statins: an opportunity lost? J Clin Hypertens (Greenwich). 2008;10:245-8.